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Abstract 
 The identification of ‘legal highs’ is challenging as they often do not match their label 
claim and contain a wide range of impurities and/or adulterants. In addition, there is a need 
for techniques to be on-site, rapid and non-destructive. The feasibility of using the in-built 
algorithms of handheld near-infrared (NIR), Raman and attenuated total reflectance Fourier 
transform-infrared (ATR-FT-IR) spectroscopy for the identification of ‘legal high’ substances 
was investigated. Spectral libraries were constructed using three substances found in ‘legal 
highs’ (i.e., dextromethorphan, 2-aminoindane and lidocaine) and their 50:50 mixtures with 
caffeine. Model dilution mixtures with caffeine (i.e., 5 – 95% m/m) and seven ‘legal high’ 
Internet products were used to test the method. The ‘legal high’ constituents in most of the 
model mixtures were identified within a minimum range of 30 – 60% m/m for NIR, 20 – 
75% m/m for Raman, and 41 – 85% m/m for ATR-FT-IR. This demonstrates that simple 
library mixtures could be used to identify test substances when the concentrations are 
variable. Below and above these levels, the test mixtures often correlated to the component in 
higher concentration. Collectively, the instruments identified the main constituents in the 
seven Internet products with varying correlation criteria. The NIR and ATR-FT-IR provided 
complementary information compared to Raman when carbohydrate cutting agents were 
added to the product, yet the Raman showed a high fluorescence signal for three products 
hindering identification. These initial studies indicate the suitability of three complementary 
techniques for rapid identification of ‘legal high’ products. Further development of spectral 
libraries, algorithms, and use of alternative Raman excitation wavelengths is needed to 
provide adequate tools for in-field analysis by non-experts.  
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1. Introduction 
 ‘Legal highs’ or new psychoactive substances (NPS) are drugs of abuse (i.e., initially 
legal) that intend to mimic the effects of illegal drug substances. They include analogues of 
well-established drugs of abuse, psychoactive substances researched in the past, and 
pharmaceutical substances that are newly abused [1]. Since 2005, the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) has investigated over 300 NPS [2]. These 
products are easily accessible via the Internet, labelled with attractive names such as ‘Trip’ 
and ‘Blurberrys’, and advertised as ‘research chemicals’, ‘bath salts’ and/or ‘not for human 
consumption’ to surpass controlled drug regulations [3]. As they are advertised as legal 
alternatives to cocaine and ecstasy, they are often perceived as safe; however, there remains 
limited information on their pharmacology. In addition, they are often taken in combination 
with other drugs/alcohol or in repetitive doses within a short timeframe [4-6]. According to 
Corkery et al., the reported deaths cases in the UK in which an NPS was implicated in a 
death rose from 10 in 2009 to 68 in 2012 [7]. 
 A key issue associated with these substances is that they often do not comply with 
their label claim, but contain a wide range of drug mixtures and/or impurities that may or 
may not be psychoactive [3,8, 9-21]. This could result in dangerous consequences, such as 
neurotoxicity, when new derivatives are taken with other stimulants as cocktails [22]. In 
addition, the consumption of unknown psychoactive substances can impact on treatment. At 
present, there are no established protocols for treating those with NPS intoxications [23]. This 
is, in part, as a result of the varied chemical composition of these products, and the fact that 
little is known about the chronic use of these substances. In an effort to identify ambiguous 
new drugs such as these, samples have been collected from both patients admitted to hospital 
[8] and Amnesty bin samples [6]. In these circumstances, samples were transported from the 
hospital to laboratories for chemical analysis. This process is often time consuming and does 
not give immediate feedback to those who would benefit in the field. This stimulates the need 
for simple and rapid techniques for the identification of these products where they are 
encountered. 
 Currently, the most common techniques used for analysis of NPS include wet 
chemical techniques such as chromatography, mass spectrometry, nuclear magnetic 
resonance spectroscopy and hyphenated techniques (e.g., gas chromatography-mass 
spectrometry and liquid chromatography-mass spectrometry) [3,8, 9-21, 24-26]. From these 
analyses, common adulterants identified in products have included stimulants such as 
caffeine; anaesthetics such as lidocaine, benzocaine and procaine; and inactive materials such 
as cellulose and talc to increase powder bulk.  
 There are limited studies on the use of laboratory-based solid-state techniques such as 
attenuated total reflectance Fourier transform-infrared (ATR-FT-IR) and Raman 
spectroscopy for the identification of ‘legal high’ products. Mainly, they have been used in 
conjunction with wet laboratory techniques to identify substances such as the phenethylamine 
2C-N [27], 5,6-methylenedioxy-2-aminoindane (MDAI) [10], and the hydrochloride salts of 
buphedrone and pentedrone [28]. The use of Raman spectroscopy as an initial screening tool 
for NPS was investigated using (3,4-methylenedioxy)amphetamine [29], β-
ketophenethylamines [30] and cathinone regioisomers [31], and showed promise for 
distinguishing drug analogues in seized samples. The examples above have been evaluated 
for lab-based instruments, which are not designed for in-field use.  
 Handheld instruments offer the advantage of carrying the laboratory to the sample. 
For example, electrochemical approaches are often a promising area for in-field detection as 
these techniques are readily transferred from the lab to the field. To this end, the use of a 
dropping mercury electrode was shown to detect mephedrone in urine [32], and more recently 
Smith et al. demonstrated the use of screen-printed electrochemical sensors for the detection 
of cathinone derivatives [33,34]. On the other hand, portable instruments are also available for 
several solid-state spectroscopic techniques such as ATR-FT-IR, near-infrared (NIR) and 
Raman. NIR and Raman spectroscopy are rapid and non-destructive, where several different 
samples can be measured within minutes. ATR-FT-IR is also a rapid technique and uses 
smaller sample amounts (i.e., a few milligrams) than the other two techniques, yet sample 
recovery is often difficult when cleaning the internal reflection element (IRE) between uses. 
A number of studies report on the use of portable ATR-FT-IR and Raman instruments for the 
identification of drugs of abuse [35-39]; however, these are mainly limited to classical drugs of 
abuse such as heroin, cocaine and amphetamine. Mabbott et al. showed the feasibility of 
using surface enhanced Raman scattering (SERS) with a portable Raman instrument for the 
detection of pure mephedrone [40]. More recently, Tsujikawa et al. investigated a number of 
psychoactive drugs including ‘legal highs’ using portable NIR with various data pre-
processing steps [41]. There are a limited number of studies in this area and in order to focus 
resources appropriately, the suitability of the various portable vibrational spectrometers 
available for the identification of ‘legal high’ substances and products has yet to be 
investigated.  
 The objective of this work is to investigate three handheld spectroscopic methods 
(i.e., NIR, Raman and ATR-FT-IR) for the identification of ‘legal high’ substances in model 
mixtures and Internet products; and to propose a strategy for their use in monitoring products 
in the field by non-experts such as nurses, regulatory authorities and police. The study 
focuses on the ‘legal high’ substances dextromethorphan, 2-aminoindane, and lidocaine; and 
related products obtained from the Internet. The approaches to analyse the products are based 
on the instruments’ in-built identification algorithms and spectral libraries composed of pure 
substances and mixtures with caffeine.  
 
2. Experimental 
2.1.Materials 
 Pure powder samples of two drugs commonly found in products available on ‘legal 
high’ websites, dextromethorphan hydrobromide (DXM) and 2-aminoindane hydrochloride 
(2AI) (Figure 1), were purchased from Sigma Aldrich. For commonly used adulterants and 
diluents, pure samples of benzocaine (BEN), caffeine (CAF), lactose (LAC), lidocaine 
hydrochloride (LID), microcrystalline cellulose (MCC), paracetamol (PAR), procaine 
hydrochloride (PRO) and talc (TAL) were purchased from Sigma Aldrich, Acros Organic and 
Fisher Scientific, and BDH laboratories. A total of seven ‘legal high’ products were 
purchased from the Internet and included five powders and two capsules. The label claim of 
the products indicated that they contained either an aminoindane derivative or DXM. 
 Model powder mixtures were prepared of 2AI/CAF, DXM/CAF and LID/CAF for use 
as method signatures and test samples. Powders composed of 50:50 2AI/CAF, DXM/CAF 
and LID/CAF were used for method signatures. Powder dilutions of the three mixture types 
containing various % m/m were constructed to have a known matrix for testing each 
instrument’s in-built identification. Table 1 shows the three mixture types each containing 
twelve dilutions and includes Mixture 1 (2AI/CAF), Mixture 2 (DXM/CAF) and Mixture 3 
(LID/CAF). The dilution mixtures were prepared by adding different amounts of pure CAF 
powder to each of 2AI, DXM and LID to get variable percentages in the range of 5 - 95% 
m/m. To test the selectivity of the instruments, a blank test set of both binary and ternary 
mixtures was prepared. The blank test sets were composed of BEN, MCC, PAR, PRO and 
TAL (i.e., common cutting agents and adulterants found in ‘legal highs’) in various 
percentages (Supplementary Data). The blank test set did not contain 2-AI, DXM, LID or 
CAF (i.e., the substances of interest in the three mixture types).  The powders were weighed 
in their original vials using a Mettler Toledo balance capable of measurements from 0.01 mg 
up to 220 g. The balance was enclosed in a safety cabinet (BIGNEAT F3-XIT). Each dilution 
was stored in a Kimble screw thread 4 ml glass vial with PTFE cap. To ensure uniformity of 
the mixtures within a vial, a VORTEX-GENIE2 (Scientific industries, Inc.) mixer was used 
to homogenise powders after the mixtures were prepared (10 min) and immediately before 
analysis (2 min).  
 
2.2.Handheld Instrumentation 
 Three handheld instruments obtained from ThermoFisher Scientific Inc. (Wilmington, 
MA) were used and included the Thermo microPHAZIR RX NIR, Thermo TruScan RM 
Raman and Thermo TruDefender FT IR analyser. The Thermo microPHAZIR RX had a 
weight of 1.25 Kg, a battery life of six hours and operated in a temperature range of -5 to 
40˚C. The spectral range of the instrument was 1600 – 2400 nm with a resolution of 11 nm. 
The Thermo TruScan RM had a weight of 0.9 Kg, a battery life of four hours and operated in 
a temperature range of -25 to 40˚C. It had a 785 nm laser excitation wavelength, an output of 
250 mW, 0.2 - 2.5 mm spot size and a 2048 element silicon charge coupled device (CCD) 
detector. The spectral range of the instrument was 250 – 2875 cm-1 with a resolution of 8 – 
10.5 cm-1. The Thermo TruDefender FT analyser (with an internal reflection element (IRE)) 
had a weight of 1.3 Kg, a battery life of four hours and operated in a temperature range of -25 
to 40˚C.	   The FT-IR utilised a broadband heated filament source and had a single-bounce 
diamond ATR with a DLTGS detector and ZnSe beamsplitter. The spectral range of the 
instrument was 650 – 400 cm-1 with a resolution of 4 cm-1. 
 
2.3.Method 
 Powders were measured through the vials using the microPHAZIR and TruScan RM. 
A few milligrams from each vial were measured through direct contact with the instrument 
nozzle via a crusher attachment when using the TruDefender FT analyser. The IRE was 
cleaned between measurements using a Kimwipe and methanol. The instruments used an 
algorithm that collected spectra until an appropriate S/N ratio was obtained. 
 Using the three instruments, signatures (i.e., high quality spectra) were taken for the 
pure substances and the 50:50 mixtures of 2AI/CAF, DXM/CAF and LID/CAF, and stored in 
the library as a method. At times, the Raman signatures took notably longer to collect than 
when using the other two instruments depending on the Raman activity of the material 
measured and the fluorescence generated by the sample. A number of test samples were 
compared against the generated methods and included the pure substances, powder dilution 
mixtures, a blank test set, and Internet products. When testing substances against the built 
methods, three scans were taken for each sample. 
 
2.4.Identification using gas chromatography mass spectrometry (GC-MS) 
 The composition of the Internet products was confirmed using gas chromatography 
mass spectrometry with electron ionisation (GC-EI-MS). A Varian 240 GC-240 MS ion trap 
instrument was used in full scan mode (range 40 – 1000 m/z). The main constituents in the 
‘legal high’ products were identified using a NIST library.  
 
3. Results and Discussion 
3.1.In-built identification method (or instrument algorithm) 
 The significance of the in-built identification algorithms, using the three instruments, 
is that they can give an immediate answer for the test product against library signatures.  
The in-built algorithm of the microPHAZIR was based on the correlation in 
wavelength space (CWS) method [42], which compares the test substance spectrum (B) 
against the library signatures (A). This is made by calculating the correlation coefficient (r) 
(Equation 1) between the standard normal variate-second derivative spectra (SNV-D2) of 
each test substance and the library signatures.  
 
 !! =    (!! −   !)(!! −   !) (!! − !)! (!! − !)!                          Equation 1                        
 
An r value of 1 meant that the spectra were identical, whereas a negative r value showed 
dissimilarity [43, 44]. However, it is difficult to get a value of 1 in practice due to noise effects. 
An r value of 0.95 was used as a threshold [43], where ≥ 0.95 the tested substance was 
considered consistent with the library spectrum and < 0.95 indicated the two substances 
exhibited differences.  
 Both the TruScan RM and the TruDefender FT analyser operated using Bayesian 
theorem. The TruScan RM operated using the same engines except that it started with 
calculating a probability value (PVAL) [45, 46] for the test substance spectrum against a 
selected library signature (Equation 2).  
 
      !   ! ! = ! ! ! !(!) !(!)                                                                 Equation 2 
Where P (A|B) is the conditional probability of A such that B exists; it is also known as the          
posterior probability. 
           P (B|A) is the conditional probability of B such that A exists; it is also known as the         
likelihood. 
          P (A) is the prior or marginal probability of A. 
         P (B) is the prior or marginal probability of B; this acts as a normalising constant. 
 
 A PVAL ≥ 0.05 meant that the test substance spectrum was considered consistent 
with the selected library signature. A PVAL below 0.05 meant that the test substance and 
library spectrum exhibited differences. If the PVAL was below 0.05, the instrument then 
worked in discovery mode where the test spectrum was compared against all library 
signatures and gave a consistent match or percentage correlation to a library signature(s). The 
percentage correlation was not quantitative, but indicated how much of the molecular signal 
from the test substance correlated to the library signature(s). No upper percentage threshold 
was used as it depended on the number of signatures matching the test spectrum. Correlation 
values < 10% were discarded due to the noise effects of these portable instruments, which is 
greater than their bench-top counterparts. The TruDefender FT analyser operated under this 
algorithm but reported the percentage correlation without giving a PVAL.  
To summarise, the NIR and ATR-FT-IR algorithms compared the test spectrum to all 
library signatures, whereas the Raman algorithm compared the spectrum to a specific 
signature first. Additionally, the Raman and ATR-FT-IR’s screen display showed both the 
associated spectra and correlation value; the NIR did not display spectra, but showed only the 
numerical correlation value. 
 
3.2.Analysis of pure substances and dilution mixtures 
3.2.1. Substance selection 
For this preliminary study, substances that were commercially available in large quantities 
were selected enabling the preparation of a variety of powder mixtures. The substances used 
to construct the model mixtures (i.e., DXM, 2-AI, LID and CAF) (Figure 1) were selected to 
evaluate a range of ‘legal’ substances currently available from Internet sources. DXM, an 
active pharmaceutical ingredient found in many cough suppressants, is known to cause 
hallucinations and phencyclidine (PCP) - like behavioural effects at high doses [47]. 
Traditionally, this substance was abused by ingesting large quantities of cough suppressant, 
but more recently DXM has become available on Internet sites in powder form. DXM abuse 
continues to increase worldwide and it is particularly popular amongst teenagers [48,49]. 2-AI 
is a conformationally rigid analogue of amphetamine and is one of the popular aminoindanes 
along with 5,6-methylenedioxy-1-aminoindane (MDAI) and 5-iodo-2-aminoindane (5-IAI) 
[22,50]. It continues to be available on a wide range of Internet sites and has been used as a 
commercially available substitute for MDAI and 5-IAI and also used in branded products [51]. 
LID was also used, as this substance, although traditionally used to cut cocaine due to its 
numbing effect, is now commonly used to cut ‘legal high’ products [3, 12, 52]. CAF, a stimulant, 
was chosen as the diluent because it is one of the major adulterants encountered in NPS [3, 52].  
3.2.2. MicroPHAZIR RX (NIR) 
The pure substances and 50:50 mixtures were consistent with their NIR signatures 
above the threshold (0.95) (Supplementary information). For the dilution mixture results 
(Table 2), Mixtures 1 (2AI/CAF) and 2 (DXM/CAF) were consistent with (i.e., values ≥ 0.95 
shown in bold) their corresponding 50:50 library signature in the range of 29.9 – 59.9% m/m 
(Mixtures 1D4 – 1D6) and 30.6 – 60.1% m/m (Mixtures 2D4 – 2D6), respectively. The range 
was larger for Mixture 3 (LID/CAF), which showed consistency with the 50:50 library 
signature in the range of 30.2 – 70.1% m/m (Mixtures 3D4 – 3D7).  
Concentrations of drug below and above these values had NIR spectra that were either 
consistent with a single substituent or did not correlate to a library signature at or above the 
0.95 threshold. For example, at ≤ 10.0% m/m 2AI, the spectra were consistent with the CAF 
signature. At concentrations ≥ 85.3% m/m 2AI, the dilutions’ spectra were consistent with the 
2AI signature. The remaining dilutions which included Mixture 1D3 and Mixtures 1D7 – 
1D9 (20.0% m/m and 69.9 – 80.1% m/m) did not result in an r value at or above the 
threshold (i.e., r ≥ 0.95). Similarly, for Mixture 2, concentrations ≤ 9.8% m/m DXM, the 
dilutions’ spectra were consistent with the CAF signature. At concentrations ≥ 75.2% m/m 
DXM, the dilutions’ spectra were consistent with the DXM signature. The remaining 
dilutions, which included Mixture 2D3 and 2D7 (20.0% m/m and 70.0% m/m), resulted in r 
values below the threshold. On the other hand, the spectra from Mixture 3 dilutions with ≤ 
20.0% m/m and ≥ 95.1% m/m LID, were consistent with the CAF and LID signatures, 
respectively. Between 75.1 – 89.7% m/m the Mixture 3 dilutions’ spectra resulted in no 
correlations above the threshold. In summary, the dilutions’ mixtures were consistent with 
the pure and 50:50 signatures when the dilution mixture concentration was close to the 
signature concentrations, yet identification of substances at the 0.95 threshold proved difficult 
for intermediate concentrations such as those for Mixtures 2D3 and 2D7. Although some r 
values were below the chosen threshold, all samples did correlate to an appropriate library 
signature with the smallest r value of 0.8606.  Thus, for mixture analysis, consideration 
should be made for possibly lowering the threshold as correlations are made to a single 
library signature and not a combination of signatures as will be seen with the TruScan RM 
and TruDefender ATR-FT-IR.  
  
3.2.3. TruScan RM (Raman) 
 The pure substances and 50:50 mixtures were consistent with their Raman signatures 
at or above the threshold (PVAL ≥ 0.05) with the exception of LID, which correlated (100%) 
to its signature in discovery mode (Supplementary information). For the dilution mixtures, 
the TruScan RM algorithm compared each mixture against their corresponding 50:50 library 
signature first. For PVALs below 0.05, the spectrum was then compared against all library 
signatures in discovery mode and gave a % correlation (Table 2). For all dilution mixtures, 
the spectra were either consistent with the 50:50 library signature (PVAL ≥ 0.05) or showed a 
% correlation in discovery mode.  
Mixtures 1 (2AI/CAF), 2 (DXM/CAF) and 3 (LID/CAF) were consistent with (i.e., 
values shown in bold in Table 2) a mixture of both components in the range of 20.0 – 74.6% 
m/m 2AI (Mixtures 1D3 – 1D8), 20.0 – 80.1% m/m DXM (Mixtures 2D3 – 2D9) and 20.0 – 
89.7% m/m LID (Mixtures 3D3 – 3D11), respectively. These results are much improved 
compared to the MicroPHAZIR (NIR), where correlations to a mixture occurred for a smaller 
% m/m range. Most of the dilution mixtures correlated to library signatures in discovery 
mode. For example, Mixture 1D3 (20.0% m/m) was initially compared to the 50:50 2AI/CAF 
signature resulting in a PVAL of 0.0118 which was below the designated threshold. The 
algorithm then compared the Mixture 1D3 spectrum to all library signatures, which correlated 
to 2AI/CAF (82%) and CAF (18%). Figure 2a shows a representative Raman screen display 
for Mixture 1D3 when using discovery mode. By comparing the spectra, the test spectrum 
shows the CAF O=C-N bending vibration at 555 cm-1 [53] and 2AI C-C chain vibrations (700-
900 cm-1).  
Concentrations of drug below and above the ranges mentioned above had Raman 
spectra that were correlated with a single substituent in discovery mode, and were consistent 
with the component in highest concentration. The 1D dilution mixtures ≤ 10.0% m/m 2AI 
(Mixtures 1D1 and 1D2) and ≥ 80.1% m/m 2AI (Mixture 1D9 - 1D12) gave spectra that were 
consistent with the signatures of CAF and 2AI respectively. For the 2D dilution mixtures, ≤ 
9.8% m/m DXM (Mixtures 2D1 and 2D2) and ≥ 84.8% m/m DXM (Mixture 2D10) were 
consistent with the CAF and DXM signatures, respectively. The 3D dilution mixtures ≤ 
10.5% m/m LID (Mixtures 3D1 and 3D2) and ≥ 95.1% m/m LID (Mixture 3D12) were 
consistent with the CAF and LID signatures, respectively. In summary, the Raman instrument 
was able to identify the main constituent(s) of each dilution mixture either by obtaining a 
PVAL ≥ 0.05 or % correlation in discovery mode. As the TruScan RM algorithm can 
correlate a spectrum to more than one library signature in discovery mode, this improved 
identification for the dilutions mixtures in comparison to the MicroPHAZIR (NIR). 
 
3.2.4. TruDefender ATR-FT-IR  
 All the pure substances were consistent with their own signature with values of 100%, 
while the 50:50 mixtures correlated to the mixture signature or the individual signatures 
(Supplementary information).  
Mixtures 2 (DXM/CAF) and 3 (LID/CAF) were consistent with (i.e., values in bold) a 
mixture of both components in the range of 30.6 – 89.8% m/m DXM (Mixtures 2D4 – 2D11) 
and 41.0 – 85.1% m/m LID (Mixtures 3D5 – 3D10), respectively (Table 2). For Mixture 1 
(2AI/CAF) dilutions, those in the range of 20.0 – 85.3% m/m 2AI (Mixtures 1D3 - 1D10) did 
not correlate to any library signatures, except for 40.3% m/m 2AI (Mixture 1D5), which 
correlated to the signatures of 2AI (56%) and CAF (30%). Figure 2b shows a representative 
ATR-FT-IR spectrum for 1D3. Although the spectrum shows absorptions from characteristic 
vibrations such as NH2 and C-H stretching (i.e., 3200 to 2500 cm-1), no correlation was found 
using the algorithm. The ATR-FT-IR in-built algorithm performed the worst out of all three 
techniques when analysing these intermediate 1D mixtures. Upon inspection of the IR spectra 
for 2AI and CAF, they both showed strong infrared absorption and had a similar distribution 
of absorption peaks in the fingerprint area, yet no strong distinctive peaks outside of this area. 
This suggests the similarity between the spectra resulted in these two compounds being 
difficult to identify in a mixture in the absence of an exactly matching library signature. This 
may have implications when using this method for analysing other amphetamine-like 
substances mixed with CAF.  
The 1D dilutions ≤ 10.0% m/m 2AI (Mixtures 1D1 and 1D2) and ≥ 90.0% m/m 2AI 
(Mixtures 1D11 and 1D12) were consistent with the signatures of CAF and 2AI, respectively. 
A study investigating a 10% m/m MDAI mixture with CAF using lab-based ATR-FT-IR, 
showed similar results where the powder matched to the CAF signature exclusively (r = 
0.995) [10]. For 2D dilutions ≤ 20.0% m/m DXM (Mixture 2D1 - 2D3) and ≥ 95.2% m/m 
DXM (Mixture 2D12), the spectra were consistent with the signatures of CAF and DXM 
respectively. Similarly, dilutions with ≤ 30.2% m/m LID (Mixtures 3D1 - 3D4) were 
consistent with the CAF signature. Dilutions with ≥ 89.7% m/m LID (Mixture 3D11 and 
3D12) gave no correlation, as CAF is a stronger Raman scatterer than LID.  
 In summary, the ATR-FT-IR experiments were successful for detecting the main 
constituents for most dilutions of the 2D and 3D mixtures. Furthermore, the instrument was 
able to identify DXM/CAF mixtures in a larger % m/m range than the other two instruments. 
However, in the case of Mixture 1D, correlations only occurred when the concentrations were 
very similar to the library signatures (i.e., pure or 50/50 mixture). The ATR-FT-IR instrument 
was only successful for identifying CAF in the 1D1 and 1D2 mixtures, CAF and 2AI in the 
1D5 mixture and 2AI in the 1D11 and 1D12 mixtures. This was likely due as a result of the 
similarity between the absorption spectra of CAF and 2AI. In contrast, LID/CAF mixtures at 
high LID concentrations did not correlate to any library signature(s). 
 
3.3.Application to ‘legal high’ products 
 The contents of the ‘legal high’ products were initially verified using GC-EI-MS, and 
the main constituents with corresponding major ion peaks for each product are shown in 
Table 3. Product 1 was labelled as 2AI but was composed of two constituents not on its label 
claim, CAF (m/z 194) and methyl phenidate (m/z 84). Products 2-6 contained a main 
constituent that was stated on their label claim. For example, products 2 and 3 were 
purchased as the products ‘Blurberry’ and ‘Pink champagne’ and were confirmed to match 
part of their label claim, 2AI (m/z 133) and CAF (m/z 194). The major ion peak for the DXM 
products 4-6 was seen at m/z 271. Product 7 was labelled as DXM, but was confirmed to 
contain CAF as the active ingredient.  
 The three spectroscopic instruments’ in-built algorithms were at times complementary 
in identifying the main constituents in the ‘legal high’ products (Table 3). The main 
constituents of all products were identified with one or two algorithms, however the 
correlation values were varied. One exception was methylphenidate in P1, which was not 
identified using the spectroscopic instruments as this reference was not present in the library.  
Using the microPHAZIR CWS in-built algorithm, all products did correlate to a 
library signature, yet only one product correlated at a value above 0.95. This sample was 
labelled as DXM (P7) and correlated to the CAF signature (r = 0.9646). This agreed with the 
GC-EI-MS analysis, which gave a major ion peak at m/z 194 corresponding to CAF. 
Products 1, 2 and 3 had correlations with CAF (0.835), 2AI/CAF (0.6767) and 2AI/CAF 
(0.3965), respectively, which were the major constituents found using GC-EI-MS. Although 
the correlation values were below 0.95 (i.e., indicating they were not an identical match), 
they do correlate to appropriate signatures as these products most likely contained other 
substituents. As mentioned previously with the dilution mixtures, it may be considered to 
lower the correlation coefficient threshold when identifying ‘legal high’ substances using this 
instrument as products are often a mixture of ingredients. Products 4-6 also gave r values 
below 0.95 ranging from 0.4265-0.5012 for MCC, which most likely was used as a cutting 
agent. Overall, NIR takes into account both the physical properties as well as the chemical 
constituents of a substances [54] and may be advantageous when comparing products 
suspected to be from the same source. 
 The TruScan RM probability in-built algorithm gave correlations for three products, 
which were labelled as DXM (P4 – P6).  The products correlated to DXM in discovery mode 
from 87-88%. Figure 3a shows the Raman spectra of P4 with library correlations to DXM 
(87%) and isobutyl chloroformate (2%), where isobutyl chloroformate was discarded as the 
% correlation was less than 10%. These products were confirmed to contain DXM using GC-
EI-MS (Table 3). Product 1 gave Raman scattering; however, did not correlate with any 
signature in discovery mode. Although this product contained CAF (m/z 194) confirmed 
using GC-EI-MS, it also contained methylphenidate, which possibly masked the CAF Raman 
signal. On the other hand, products 2, 3 and 7 showed a large fluorescence background with 
little discernable peaks indicating the products were cut with a highly fluorescent substance. 
For example, the Raman spectrum of Pink champagne (P3) shows a broad featureless 
spectrum with no library correlation found (Figure 3c). The use of a longer wavelength can 
reduce fluorescence, which may be needed for analysing certain ‘legal high’ products. In 
some circumstances, when a Raman active drug is present in high concentration the Raman 
scattering may still be seen with minimum fluorescence despite the presence of impurities. 
This was observed for seized cathinone samples that were cut by calcium carbonate and other 
impurities [30]. 
 The TruDefender probability algorithm correlations varied markedly from the 
previous two algorithms. Whereas P4 – P6 were consistent with DXM using the TruScan 
RM, these products correlated to other existing libraries in the instrument as mixtures of 
starch, maltodextrin, amylose and amylopectin. An example of this is shown in Figure 3b 
where the FT-IR spectrum of P4 and its library correlations are represented. This indicates 
that the DXM present in these products was not pure and the additives used were likely 
carbohydrate in nature. Carbohydrates (e.g., starch) contain many polar C-O and O-H bonds, 
which are strong infrared absorbers and weak Raman scatterers. These results were similar to 
those seen for the NIR analysis, where these samples matched to the carbohydrate MCC. The 
use of the TruScan RM would be advantageous for quick identification of ‘legal high’ 
products that contain bulking agents of this nature. Products 3 and 7 had the highest 
correlation to CAF, which was confirmed using GC-EI-MS. These products also correlated to 
the LID/CAF signature, but as no LID was found using GC-EI-MS, this seemed to be a false 
positive due to the CAF being a stronger Raman scatterer in that particular Model mixture. 
For Pink champagne (P3), the product correlated to CAF at 72%, but LID/CAF at 3%, thus 
the latter value was discarded (i.e., below 10%) (Figure 3d). The presence of CAF in ‘legal 
high’ products, either in pure or mixed form, using ATR-FT-IR has been previously reported 
[10]. Product 2, Blurberry, produced an ATR-FT-IR signal, but the results were non-
reproducible and correlated to a range of signatures including 2AI/CAF, LID/CAF, 
DXM/CAF, and CAF. Although the product was vortexed before each reading, the product 
may have retained some heterogeneity impacting on the reproducibility of the signal. Product 
1 showed many peaks in the fingerprint area, but due to the presence of methyl phenidate, no 
match was found. 
 
4. Conclusion 
 The use of a library method composed of pure and 50:50 mixtures for three handheld 
instruments shows promise for identification of ‘legal high’ substances. A summary of the 
instruments’ performance for both dilution mixtures and ‘legal high’ Internet products is 
shown in Table 4. For the dilution mixtures, the % m/m range where a mixture was 
successfully identified was different for the three instruments, with the TruScan RM (Raman) 
performing the best for all mixtures with a minimum range of 20.0 – 74.6% m/m. The 
identification of mixtures using the MicroPHAZIR (NIR) was limited as the algorithm 
correlated to only a single library signature and not a combination as with the other 
instruments. Outside these ranges, the powder mixtures were in most cases correlated to the 
pure substance in highest concentration in the default and/or discovery mode, the exceptions 
being 2AI/CAF (1D) and LID/CAF (3D) mixtures analysed by ATR-FT-IR. This 
demonstrates that simple library mixtures could be used to identify substances when the 
concentrations are variable. When analysing the Internet products, most active ingredients in 
the products were identified with one or two instruments, however the correlation values 
were varied. The three techniques were affected differently by the presence of cutting agents 
and adulterants in the ‘legal high’ products. Both NIR and ATR-FT-IR were sensitive to the 
presence of carbohydrate cutting agents, whereas the Raman was not. However, three 
products showed a high fluorescence signal during Raman analysis, which hindered 
identification. Thus, future efforts should focus on building more extensive NPS libraries, 
examination of thresholds used for NIR, evaluation of a lower energy wavelength for Raman 
analysis to reduce fluorescence, and investigation of alternative algorithms. 
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Table 1 Details of the dilution mixtures prepared1 
Mixture 
number 
Mixture 
type 
Drug content  
(% m/m) 
Caffeine content  
(% m/m) 
Mixture 1D1 2AI/CAF   4.9 95.1 
Mixture 1D2 2AI/CAF 10.0 90.0 
Mixture 1D3 2AI/CAF 20.0 80.0 
Mixture 1D4 2AI/CAF 29.9 70.1 
Mixture 1D5 2AI/CAF 40.3 59.7 
Mixture 1D6 2AI/CAF 59.9 40.1 
Mixture 1D7 2AI/CAF 69.9 30.1 
Mixture 1D8 2AI/CAF 74.6 25.4 
Mixture 1D9 2AI/CAF 80.1 19.9 
Mixture 1D10 2AI/CAF 85.3 14.7 
Mixture 1D11 2AI/CAF 90.0 10.0 
Mixture 1D12 2AI/CAF 95.1   4.9 
Mixture 2D1 DXM/CAF   5.5 94.5 
Mixture 2D2 DXM/CAF   9.8 90.2 
Mixture 2D3 DXM/CAF 20.0 80.0 
Mixture 2D4 DXM/CAF 30.6 69.4 
Mixture 2D5 DXM/CAF 39.9 60.1 
Mixture 2D6 DXM/CAF 60.1 39.9 
Mixture 2D7 DXM/CAF 70.0 30.0 
Mixture 2D8 DXM/CAF 75.2 24.8 
Mixture 2D9 DXM/CAF 80.1 19.9 
Mixture 2D10 DXM/CAF 84.8 15.2 
Mixture 2D11 DXM/CAF 89.8 10.2 
Mixture 2D12 DXM/CAF 95.2   4.8 
Mixture 3D1 LID/CAF   5.0 95.0 
Mixture 3D2 LID/CAF 10.5 89.5 
Mixture 3D3 LID/CAF 20.0 80.0 
Mixture 3D4 LID/CAF 30.2 69.8 
Mixture 3D5 LID/CAF 41.0 59.0 
Mixture 3D6 LID/CAF 60.4 39.6 
Mixture 3D7 LID/CAF 70.1 29.9 
Mixture 3D8 LID/CAF 75.1 24.9 
Mixture 3D9 LID/CAF 79.7 20.3 
Mixture 3D10 LID/CAF 85.1 14.9 
Mixture 3D11 LID/CAF 89.7 10.3 
Mixture 3D12 LID/CAF 95.1   4.9 
1D; dilution number, AI: aminoindane hydrochloride, CAF: caffeine,  
DXM: dextromethorphan hydrobromide, LID: lidocaine hydrochloride, 
%m/m: percentage mass per mass. 
  
 
Table 2 Mean comparison values of the dilution mixtures using  
hand-held NIR, Raman and ATR-FT-IR spectroscopy1 
Substance              NIR           Raman          ATR-FT-IR 
 library 
signature 
r value2 library 
signature 
PVAL3 or 
correlation (%)4 
library 
signature(s) 
correlation 
(%)4 
Mixture 1D1 CAF 0.9871 CAF 100* CAF 100 
Mixture 1D2 CAF 0.9752 CAF 100* CAF 100 
Mixture 1D3 CAF 0.8988 2AI/CAF 82* None     0 
   CAF 18*   
Mixture 1D4 2AI/CAF 0.9947 2AI/CAF 0.3159 None     0 
Mixture 1D5 2AI/CAF 0.9746 2AI/CAF 0.3717 2AI 
CAF 
  56 
  30 
Mixture 1D6 2AI/CAF 0.9477 2AI 73* None     0 
   CAF 27*   
Mixture 1D7 2AI 0.8866 2AI/CAF 0.4228 None     0 
Mixture 1D8 2AI 0.9218 2AI/CAF 0.3929 None     0 
Mixture 1D9 2AI 0.8862 2AI 97* None     0 
Mixture 1D10 2AI 0.9845 2AI 95* None     0 
Mixture 1D11 2AI 0.9823 2AI 100* 2AI 100 
Mixture 1D12 2AI 0.9981 2AI 100* 2AI 100 
       
Mixture 2D1 CAF 0.9842 CAF 100* CAF 100 
Mixture 2D2 CAF 0.9578 CAF 100* CAF 100 
Mixture 2D3 DXM/CAF 0.8909 DXM/CAF 89* CAF   97 
   CAF 11*   
Mixture 2D4 DXM/CAF 0.9487 DXM/CAF 0.0480 DXM/CAF 100 
Mixture 2D5 DXM/CAF 0.9708 DXM/CAF 0.4447 DXM/CAF 100 
Mixture 2D6 DXM/CAF 0.9485 DXM/CAF 0.1943 DXM/CAF 
DXM 
  88 
  11 
Mixture 2D7 DXM 0.9320 DXM 
DXM/CAF 
83* 
16 
DXM 
DXM/CAF 
  68 
  31 
Mixture 2D8 DXM 0.9501 DXM 
DXM/CAF 
83* 
16* 
DXM/CAF 
DXM 
  75 
  24 
Mixture 2D9 DXM 0.9587 DXM 
DXM/CAF 
87* 
12* 
DXM/CAF 
DXM 
  70 
  28 
Mixture 2D10 DXM 0.9912 DXM 93* DXM 
DXM/CAF 
  80 
  19 
Mixture 2D11 DXM 0.9928 DXM 96* DXM/CAF 
DXM 
  86 
  13 
Mixture 2D12 DXM 0.9979 DXM 100* DXM 100 
       
Mixture 3D1 CAF 0.9940 CAF 100* CAF 100 
Mixture 3D2 CAF 0.9914 CAF 100* CAF 100 
Mixture 3D3 CAF 0.9797 LID/CAF 0.0453 CAF 100 
Mixture 3D4 LID/CAF 0.9721 LID/CAF 0.0552 CAF   95 
Mixture 3D5 LID/CAF 0.9959 LID/CAF 0.2515 LID/CAF 100 
Mixture 3D6 LID/CAF 0.9751 LID/CAF 0.0796 LID/CAF 100 
Mixture 3D7 LID/CAF 0.9581 LID/CAF 0.2131 LID/CAF 100 
Mixture 3D8 LID/CAF 0.9386 LID/CAF 0.2545 LID/CAF 100 
Mixture 3D9 LID 0.8606 LID/CAF 55* LID/CAF   90 
   LID 27*   
Mixture 3D10 LID 0.9067 LID 79* LID/CAF 100 
   LID/CAF 20*   
Mixture 3D11 LID 0.9374 LID 87* None     0 
   LID/CAF 12*   
Mixture 3D12 LID 0.9848 LID 100* None     0 
1D; dilution number, AI: aminoindane hydrochloride, CAF: caffeine, DXM: dextromethorphan hydrobromide, LID: lidocaine hydrochloride. 
The numbers in bold indicate a match for the test substance. 
2 r value: correlation coefficient value 
3 PVAL: probability value of the test substance spectrum against the selected library spectrum. A PVAL above 0.05 indicates that the test 
spectrum is consistent with the 50:50 library signature; the asterisk (*) indicates a PVAL < 0.05 where the algorithm then compared the test 
substances to other signatures in discovery mode. 
4Correlation (%):  indicates how much the test spectrum is similar to the matching library signature(s).  
 
Table 3 Mean comparison values of the ‘legal high’ products using hand-held NIR, Raman and ATR-FT-IR 
spectroscopy; and corresponding GC-EI-MS results1 
1P: product, 2AI: 2-aminoindane hydrochloride, CAF: caffeine, DXM: dextromethorphan hydrobromide, LID: lidocaine, MCC: 
microcrystalline cellulose. The numbers in bold indicate the test substance is consistent with the library signature. 
2 r value: correlation coefficient value 
3Correlation (%):  indicates how much the test spectrum is similar to the library signature(s).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Product  Label claim            NIR           Raman         ATR-FT-IR         GC-EI-MS         
  library 
signature 
r value2 library 
signature 
correlation 
(%)3 
library 
signature 
correlation 
(%)3 
match Major ion peak 
(m/z) 
 P1 2AI CAF 0.8535 None 0 None 0 CAF 
Methyl 
phenidate 
194 
84 
 P2 Blurberry: 
Aminoindane, 
Caffeine, 
Cola vera, 
Aminoacid  
complex 
2AI/CAF 0.6767 None 0 Non-
reproducible 
 2AI 
CAF 
133 
194 
 P3 Pink champagne: 
Aminoindane, 
Caffeine, 
Cola vera, 
Aminoacid  
complex 
2AI/CAF 0.3965 None 0 CAF 
 
 
72 
 
CAF 
2AI 
194 
133 
 P4 DXM MCC 0.4568 DXM 
 
87 
 
Starch, 
Maltodextrin; 
Amylose, 
Amylopectin 
65 
 
12 
 
DXM 271 
 P5 DXM MCC 0.4265 DXM 
 
 
88 
 
Starch, 
Maltodextrin; 
Amylose, 
Amylopectin 
60 
 
13 
DXM 271 
 P6 DXM MCC 0.5012 DXM 
 
88 
 
Starch, 
Maltodextrin; 
Amylose, 
Amylopectin 
57 
 
14 
 
DXM 271 
 P7 DXM CAF 0.9646 None 0 CAF 
LID/CAF 
58 
26 
CAF 194 
 
 
Table 4 A summary of the instruments’ performance for both dilution mixtures and ‘legal high’ Internet 
products using hand-held NIR, Raman and ATR-FT-IR spectroscopy. 
Handheld 
technique 
Analysis of 
dilution mixtures 
Range where a mixture 
was identified for the 
dilution mixtures 
Analysis of 
‘legal high’ products 
Identification results 
for ‘legal high’ 
products 
MicroPHAZIR 
NIR 
Appropriate library 
correlations were 
found for all mixtures; 
not all above the 0.95 
threshold 
 
r values ≥ 0.95 
threshold: 
1D 29.9 – 59.9% m/m 
2D 30.6 – 60.1% m/m 
3D 30.2 – 70.1% m/m 
Appropriate library 
correlations were found 
for all products; not all 
above the 0.95 threshold 
Active ingredients 
were identified in P1-3 
and P7. 
 
Cutting agents were 
identified in P4-6. 
TruScan RM 
Raman 
Appropriate library 
correlations were 
found for all mixtures 
using the default or 
discovery mode. 
PVAL ≥ 0.05 or % 
correlation: 
1D 20.0 – 74.6% m/m 
2D 20.0 – 80.1% m/m 
3D 20.0 – 89.7% m/m 
Appropriate library 
correlations were found 
for only 3 out of 7 
products; fluorescence 
masked the Raman 
signal in 3 products. 
Active ingredients 
were identified in  
P4-6. 
 
No cutting agents 
were identified. 
TruDefender 
ATR-FT-IR 
Appropriate library 
correlations were 
found for all 2D 
mixtures, but no 
correlations for some 
1D and 3D mixtures. 
% correlation: 
1D 40.3% m/m 
2D 30.6 – 89.8% m/m 
3D 41.0 – 85.1% m/m 
Appropriate library 
correlations were found 
for 4 out of 7 products; 
other products did not 
correlate to a signature, 
were non-reproducible, 
or resulted in a false 
positive. 
Active ingredients 
were identified in P3 
and P7. 
 
Cutting agents were 
identified in P4-6. 
Figure Captions 
 
Figure 1: The chemical structures of (a) dextromethorphan, (b) 2-aminoindane, (c) lidocaine, 
and (d) caffeine. 
Figure 2: Screen display from handheld instruments showing a) a Raman spectrum of 
Mixture 1D3 (2AI/CAF 20:80% m/m) (black line) compared against the signatures of 
2AI/CAF (82%) (red line) and CAF (18%) (blue line), and b) an ATR-FT-IR spectrum of 
Mixture 1D3 (2AI/CAF 20:80% m/m) with no match found. 
Figure 3: Screen display from handheld instruments showing a) a Raman spectrum of DXM 
P4 (black line) compared against the signatures of DXM (87%) (red line) and isobutyl 
chloroformate (2%) (blue line), b) an ATR-FT-IR spectrum of DXM P4 (black line) 
compared against the signatures of starch/maltodextrin (65%) (red line) and 
amylose/amylopectin (12%) (blue line), c) a Raman spectrum of Pink champagne P3 (black 
line) with no match found, and d) an ATR-FT-IR spectrum of Pink champagne P3 (black 
line) compared against the signatures of CAF (72%) (red line) and LID/CAF (3%) (blue line). 
 
 
 
 
 
 
 
 
 
 
  
Figure 1: The chemical structures of (a) dextromethorphan, (b) 2-aminoindane, (c) lidocaine, 
and (d) caffeine. 
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Figure	  2:	  Screen	  display	  from	  handheld	  instruments	  showing	  a)	  a	  Raman	  spectrum	  of	  Mixture	  1D3	  (2AI/CAF	  20:80%	  m/m)	  (black	  line)	  compared	  against	  the	  signatures	  of	  2AI/CAF	  (82%)	  (red	  line)	  and	  CAF	  (18%)	  (blue	  line),	  and	  b)	  an	  ATR-­‐FT-­‐IR	  spectrum	  of	  Mixture	  1D3	  (2AI/CAF	  20:80%	  m/m)	  with	  no	  match	  found.	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Figure	  3:	  Screen	  display	  from	  handheld	  instruments	  showing	  a)	  a	  Raman	  spectrum	  of	  DXM	  P4	  (black	  line)	  compared	  against	  the	  signatures	  of	  DXM	  (87%)	  (red	  line)	  and	  isobutyl	  chloroformate	  (2%)	  (blue	  line),	  b)	  an	  ATR-­‐FT-­‐IR	  spectrum	  of	  DXM	  P4	  (black	  line)	  compared	  against	  the	  signatures	  of	  starch/maltodextrin	  (65%)	  (red	  line)	  and	  amylose/amylopectin	  (12%)	  (blue	  line),	  c)	  a	  Raman	  spectrum	  of	  Pink	  champagne	  P3	  (black	  line)	  with	  no	  match	  found,	  and	  d)	  an	  ATR-­‐FT-­‐IR	  spectrum	  of	  Pink	  champagne	  P3	  (black	  line)	  compared	  against	  the	  signatures	  of	  CAF	  (72%)	  (red	  line)	  and	  LID/CAF	  (3%)	  (blue	  line).	  
